Presentation TCT 2024 TCT 235: Efficacy and Safety of Bivalirudin and Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients Who Underwent Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis Presenter: Hamza Naveed October 28, 2024
Presentation TCT 2023 TCT 215: Safety of Bivalirudin Versus Heparin in Patients With ST-elevation Myocardial Infarction: a Systematic Review and Meta-analysis: Presenter: Mostafa Elbanna October 26, 2023
Presentation TCT 2023 Bivalirudin Is the Most Evidence Based Antithrombin Agent for Primary PCI Presenter: Gregg Stone October 25, 2023
Presentation TCT 2020 Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin Versus Heparin in Acute Myocardial Infarction Presenter: Gregg Stone October 14, 2020
Presentation TCT 2018 The Case for Bivalirudin With Radial (and Femoral) Access Presenter: John A. Bittl, C. Michael Gibson, Carey D. Kimmelstiel September 23, 2018
Presentation TCT 2017 VALIDATE-SWEDEHEART NSTEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With NSTEMI Presenter: Thomas F. Luscher, David Erlinge October 31, 2017
Presentation TCT 2017 VALIDATE-SWEDEHEART STEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With STEMI Presenter: Y. S. Chandrashekhar, David J. Moliterno, Stefan K. James October 31, 2017
Presentation TCT 2017 Why I Prefer Bivalirudin for Primary PCI in STEMI! Presenter: Michael S. Lee, Dirk Sibbing, Uwe Zeymer October 30, 2017
Presentation TCT 2016 Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials Presenter: A. Michael Lincoff, Franz-Josef Neumann, John A. Bittl October 30, 2016
Presentation TCT 2016 Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion? Presenter: A. Michael Lincoff, Franz-Josef Neumann, Gregg W. Stone October 30, 2016
Presentation TCT 2016 Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI! Presenter: A. Michael Lincoff, Franz-Josef Neumann, Harvey D. White October 30, 2016
Presentation TCT 2016 Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI! Presenter: A. Michael Lincoff, Franz-Josef Neumann, Jorge F. Saucedo October 30, 2016
Presentation TCT 2016 Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI! Presenter: A. Michael Lincoff, Franz-Josef Neumann October 30, 2016
Presentation TCT 2015 Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients? Presenter: Carlo Briguori, Roxana Mehran, Carey D. Kimmelstiel October 15, 2015
Presentation TCT 2015 BRAVO 3: A Prospective Randomized Trial of Bivalirudin Versus Heparin in Patients Undergoing Transcatheter Aortic Valve Replacement Presenter: Thierry Lefevre October 15, 2015
Presentation TCT 2015 Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Unfractionated Heparin! Presenter: John A. Bittl, Robert A. Harrington, Michael S. Lee October 12, 2015
Presentation TCT 2015 Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Bivalirudin! Presenter: John A. Bittl, Robert A. Harrington, George D. Dangas October 12, 2015
Presentation TCT 2015 Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union? Presenter: John A. Bittl, Robert A. Harrington, Harvey D. White October 12, 2015
Presentation TCT 2015 Bivalirudin Pearls: Necessity With Radial Access, Infusion Dose and Duration, Use in CKD, and More Presenter: John A. Bittl, Robert A. Harrington, Philippe Gabriel Steg October 12, 2015
Presentation TCT 2015 Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results Presenter: John A. Bittl, Robert A. Harrington, Marco Valgimigli October 12, 2015